Harvard Bioscience Inc.
HBIO
Get informed when a big investor buys or sells
+ FollowMarket Cap$33.74M
Close$
$-3.04
143.6% downside
Current Fair Value
143.6% downsideOvervalued by 143.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $33.74 Million |
|---|---|
| Enterprise Value | $75.04 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-12.8 |
| Beta | 1.49 |
| Outstanding Shares | 4,526,000 |
Return
| Return on Equity | -140.36% |
|---|---|
| Return on Assets | -13.65% |
| Return on Invested Capital | 97.04% |
Valuation & Multiples
| P/E Ratio | -3.22 |
|---|---|
| PEG | -11.69 |
| Price to Sales | 0.37 |
| Price to Book Ratio | 6.97 |
| Enterprise Value to Revenue | 0.85 |
| Enterprise Value to EBIT | 1.5 |
| Enterprise Value to Net Income | -8 |
| Total Debt to Enterprise | 0.64 |
| Debt to Equity | 6.44 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 11, 2026
EPS Estimate
$-0.21
Average shareholder expectationRevenue Estimate
$21.45 M
Average shareholder expectationNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$-0.17
Average shareholder expectationRevenue Estimate
$21.80 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 35.45%▼ 3.88% |
|---|---|
| Total Invested | $7.73M▼ 33.84% |
| Investors Holding | 36▼ 28.00% |
ESG Score
No data